Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Shenzhen Hepalink Pharmaceutical Group Co Debt-to-Equity Related Terms
Shenzhen Hepalink Pharmaceutical Group Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Hepalink Pharmaceutical Group Co Debt-to-Equity Chart
Shenzhen Hepalink Pharmaceutical Group Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Hepalink Pharmaceutical Group Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen Hepalink Pharmaceutical Group Co Debt-to-Equity vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a Debt-to-Equity of 0.27 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Shenzhen Hepalink Pharmaceutical Group Co and its competitors. This is 46% below median its historical median of 0.50. Over the past decade, Shenzhen Hepalink Pharmaceutical Group Co's Debt-to-Equity has ranged from 0.25 to 0.93. According to the industry distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #394 out of 809 companies in the Drug Manufacturers industry, placing it in the top 48.7%.
Is Shenzhen Hepalink Pharmaceutical Group Co's Debt-to-Equity too high?
Shenzhen Hepalink Pharmaceutical Group Co's current Debt-to-Equity of 0.27 is 46% below median its 10-year median of 0.50. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 0.93. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Shenzhen Hepalink Pharmaceutical Group Co's value of 0.27 is 3.6% below this industry median. Based on the distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #394 out of 809 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shenzhen Hepalink Pharmaceutical Group Co has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Hepalink Pharmaceutical Group Co's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #394 out of 809 companies for Debt-to-Equity. This puts Shenzhen Hepalink Pharmaceutical Group Co in the upper half of its industry. The industry median Debt-to-Equity is 0.28. Shenzhen Hepalink Pharmaceutical Group Co's value of 0.27 is 3.6% below this benchmark. Historically, Shenzhen Hepalink Pharmaceutical Group Co's own Debt-to-Equity has ranged from 0.25 to 0.93 over the past decade. While the company's 10-year median is 0.50 vs. the industry median of 0.28, Shenzhen Hepalink Pharmaceutical Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen Hepalink Pharmaceutical Group Co's current Debt-to-Equity of 0.27 is 3.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Shenzhen Hepalink Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen Hepalink Pharmaceutical Group Co's current Debt-to-Equity is 0.27, which is 46% below median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Hepalink Pharmaceutical Group Co stock overvalued right now?
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a current Debt-to-Equity of 0.27. The stock's GF Value™ is $0.48, compared to a current price of $0.47 — trading 2.2% below its estimated fair value. The current Debt-to-Equity is 0.27, which is 46% below median its 10-year median of 0.50 and 3.6% below the Drug Manufacturers industry median of 0.28. Shenzhen Hepalink Pharmaceutical Group Co's overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Shenzhen Hepalink Pharmaceutical Group Co (SHEZF), the current Debt-to-Equity is 0.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen Hepalink Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of $0.47 is trading 2.2% below its estimated GF Value™ of $0.48.
Key valuation signals for SHEZF:
Debt-to-Equity: 0.27 (46% below median its 10-year median of 0.50)
GF Value™: $0.48 vs. price of $0.47 (2.2% below fair value)
Industry Position: 3.6% below the Drug Manufacturers median (#394 of 809)
No single metric tells the full story. See the SHEZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company. Along with its subsidiary, it is engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development in Asia, Europe, North America, and Australia, and investment business in Asia and North America. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products; Active pharmaceutical ingredients; CDMO business; and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from Europe and the USA.
73GF Score
Get the complete analysis for SHEZF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHEZF has been successfully added to your 
